Preclinical studies have shown synergy in the combination of tifcemalimab (anti-BTLA antibody) with toripalimab (anti-PD-1 antibody) in lymphoma. Here, the authors report a clinical trial investigating tifcemalimab alone and in combination with toripalimab in patients with relapsed or refractory lymphoma.
